The Patent Finder
US

Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity

US 9,416,157 In force
OverviewFamilyAssignmentsSources & methods

Term ends Dec 11, 2026 · Medium confidence

Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 8,124,721), so the cap could be lower.

Filed Jan 27, 2012 as application 13/360,163 · Granted Aug 16, 2016
Base term plus 906 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
20 years from filing
2006 2026
Clock starts
Oct 4, 2006
Term ends
Dec 11, 2026
Granted
Aug 16, 2016
base term patent term adjustment fee events Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
906
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,124,721, US 8,791,061.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 906 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 2 of 2 maintenance fees are paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Oct 4, 2006, when application PCT/CA2006/001650, the earliest non-provisional in its chain, was filed (this one was filed Jan 27, 2012)Oct 4, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+906 days, USPTO patent term adjustment recordMar 28, 2029High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 8,124,721, US 8,791,061)capped to Dec 11, 2026Medium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderDec 11, 2026Medium confidence

This family

US 8,124,721In force
no later than Apr 2028
no later than Apr 2028
US 9,416,157this patent
Dec 2026
Dec 2026
US 8,791,061In force
Dec 2026
Dec 2026
3 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jan 14, 2013
Reel 29619, frame 868
Inimex Pharmaceuticals, Inc.Soligenix, Inc.Assignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited